Our consultancy provides strategic direction and tactical execution for development of novel pharmaceuticals and medical devices
Development
Medical product development is a complex, expensive, risky venture. How does one get from early findings to an approved product? How do you get to the key milestones as rapidly and efficiently as possible?
Gary Novack, Ph.D.
Gary D. Novack, Ph.D., President of PharmaLogic Development, Inc. has decades of experience in successful product development. Together with his team of senior experts, PharmaLogic can help you execute that plan.
Expertise
In our 25+ years working in manifold therapeutic areas with pharmaceuticals, biologics and devices, the firm’s particular expertise is in local therapy (ophthalmology and dermatology).
Based upon decades of successful product development experience, PharmaLogic Development, Inc., can help you develop and execute a strategic plan for your product. Working in manifold therapeutic areas with pharmaceuticals, biologics and devices, our expertise is in local therapy (ophthalmology and dermatology).
Dr. Novack states “The more I work in the development of new pharmaceuticals, the more I see that early development is a complex interaction of pharmaceutics (formulation), safety assessment (local and systemic), and clinical planning. Not only do we help plan and execute what needs to be done, but what needs to be done when.”
Many of his experiences and unique perspectives in product development may be found in the over two dozen editorials he has written as a contributing editor to The Ocular Surface.
NDA Partners Featured in Article on Growth of Pharma Disruptors
NDA Partners LLC, a consultancy of which I am a member, was featured in a news article in Business Worldwide. The article notes that the pharmaceutical and medical device industry has the most complex regulations of any industry. They take at the unique consultancy...
read morePredatory journals – just say no!
In the 10 May 2019 issue of Science magazine, Assistant Professor of the University of Florida, Alan H Chambers, writes about his experience with a predatory journal. In a moment of weakness after rejection of a manuscript, he submitted it to a newly launched...
read moreSonoma Eye – Dr. Novack chair symposium on research and outcomes
At the 3rd Annual Sonoma Eye, meeting, Dr. Novack chaired a symposium on two areas of interest - basic research in ocular inflammation and retinal disease and clinical outcomes. Dr. Novack presented current thinking on endpoints in approvals of novel therapeutics in...
read more